A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

A. Lipton; H. A. Harvey; R. J. Santen; A. Boucher; D. White; A. Bernath; R. Dixon; G. Richards; A. Shafik

doi:10.1002/1097-0142(19821201)50:11<2265::AID-CNCR2820501106>3.0.CO;2-%23

A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

A. Lipton, H. A. Harvey, R. J. Santen, A. Boucher, D. White, A. Bernath, R. Dixon, G. Richards, A. Shafik

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

The authors compared antiestrogen therapy (tamoxifen) with an estrogen suppression regimen (aminoglutethimide‐hydrocortisone) in postmenopausal women with metastatic breast carcinoma. Ten of 24 patients (41.5%) who received Tamoxifen experienced an objective tumor regression (three complete, seven partial remissions), whereas ten of 21 women (47.5%) receiving Aminoglutethimide responded (zero complete, ten partial remissions). The median duration of response was similar, 13 months for tamoxifen versus ten months for aminoglutethimide. The site of tumor involvement appears to be important in choosing between these hormonal treatments. Aminoglutethimide appears to offer a greater chance of response in patients with bone involvement.

Original language	English (US)
Pages (from-to)	2265-2268
Number of pages	4
Journal	Cancer
Volume	50
Issue number	11
DOIs	https://doi.org/10.1002/1097-0142(19821201)50:11<2265::AID-CNCR2820501106>3.0.CO;2-%23
State	Published - Dec 1 1982

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/1097-0142(19821201)50:11<2265::AID-CNCR2820501106>3.0.CO;2-%23

Cite this

@article{f0823f376ccc44e7a870112218d69cea,

title = "A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer",

abstract = "The authors compared antiestrogen therapy (tamoxifen) with an estrogen suppression regimen (aminoglutethimide‐hydrocortisone) in postmenopausal women with metastatic breast carcinoma. Ten of 24 patients (41.5%) who received Tamoxifen experienced an objective tumor regression (three complete, seven partial remissions), whereas ten of 21 women (47.5%) receiving Aminoglutethimide responded (zero complete, ten partial remissions). The median duration of response was similar, 13 months for tamoxifen versus ten months for aminoglutethimide. The site of tumor involvement appears to be important in choosing between these hormonal treatments. Aminoglutethimide appears to offer a greater chance of response in patients with bone involvement.",

author = "A. Lipton and Harvey, {H. A.} and Santen, {R. J.} and A. Boucher and D. White and A. Bernath and R. Dixon and G. Richards and A. Shafik",

year = "1982",

month = dec,

day = "1",

doi = "10.1002/1097-0142(19821201)50:11<2265::AID-CNCR2820501106>3.0.CO;2-%23",

language = "English (US)",

volume = "50",

pages = "2265--2268",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "11",

}

TY - JOUR

T1 - A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

AU - Lipton, A.

AU - Harvey, H. A.

AU - Santen, R. J.

AU - Boucher, A.

AU - White, D.

AU - Bernath, A.

AU - Dixon, R.

AU - Richards, G.

AU - Shafik, A.

PY - 1982/12/1

Y1 - 1982/12/1

N2 - The authors compared antiestrogen therapy (tamoxifen) with an estrogen suppression regimen (aminoglutethimide‐hydrocortisone) in postmenopausal women with metastatic breast carcinoma. Ten of 24 patients (41.5%) who received Tamoxifen experienced an objective tumor regression (three complete, seven partial remissions), whereas ten of 21 women (47.5%) receiving Aminoglutethimide responded (zero complete, ten partial remissions). The median duration of response was similar, 13 months for tamoxifen versus ten months for aminoglutethimide. The site of tumor involvement appears to be important in choosing between these hormonal treatments. Aminoglutethimide appears to offer a greater chance of response in patients with bone involvement.

AB - The authors compared antiestrogen therapy (tamoxifen) with an estrogen suppression regimen (aminoglutethimide‐hydrocortisone) in postmenopausal women with metastatic breast carcinoma. Ten of 24 patients (41.5%) who received Tamoxifen experienced an objective tumor regression (three complete, seven partial remissions), whereas ten of 21 women (47.5%) receiving Aminoglutethimide responded (zero complete, ten partial remissions). The median duration of response was similar, 13 months for tamoxifen versus ten months for aminoglutethimide. The site of tumor involvement appears to be important in choosing between these hormonal treatments. Aminoglutethimide appears to offer a greater chance of response in patients with bone involvement.

UR - http://www.scopus.com/inward/record.url?scp=0020382501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020382501&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19821201)50:11<2265::AID-CNCR2820501106>3.0.CO;2-%23

DO - 10.1002/1097-0142(19821201)50:11<2265::AID-CNCR2820501106>3.0.CO;2-%23

M3 - Article

C2 - 6754061

AN - SCOPUS:0020382501

SN - 0008-543X

VL - 50

SP - 2265

EP - 2268

JO - Cancer

JF - Cancer

IS - 11

ER -

A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this